Mefloquine one. Plasma concentrations of the (–)-enantiomer are significantly higher than those for the (+)-enantiomer, and the pharmacokinetics between the two enantiomers are significantly different. The (+)-enantiomer has a shorter half-life than the (–)-enantiomer. According to some research, the (+)-enantiomer is more effective in treating malaria, and the (–)-enantiomer specifically binds to adenosine receptors in the central nervous system, which may explain some of its psychotropic effects. Mefloquine was formulated at Walter Reed Army Institute of Research (WRAIR) in the 1970s shortly after the end of the Vietnam war. Mefloquine was number 142,490 of a total of 250,000 antimalarial compounds screened
People for the Ethical Treatment of Animals v. Doughney court ruled that Doughney violated the ACPA. However, the court further held that PETA was not entitled to damages because Doughney registered and used the domain prior to ACPA's enactment. Instead Doughney was merely required to surrender the domain. The court ruled that PETA was ineligible for an award of attorney's fees because Doughney did not maliciously infringe the trademark because he was creating a parody and had a First Amendment right to do so. People for the Ethical Treatment of Animals v. Doughney People for the Ethical Treatment of Animals v. Doughney, 263 F.3d 359 (4th Cir. 2001), was